American Society of Hematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Carteyva, JW Therapeutics, Large B-cell lymphoma, lymphoma, NMPA, relmacabtagene autoleucel
JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in people with second-line large B-c..